Impact Therapeutics (英派药业) Pre-IPO: Thoughts on Valuation
Impact Therapeutics: We provided a risk-adjusted SOTP of USD 589m. Valuation is anchored by senaparib's approved OC franchise.
311 Views
Impact Therapeutics (英派药业) Pre-IPO: Post Senaparib Commercialization, What's Next?
Impact Therapeutics PHIP updates: advances senaparib to NRDL reimbursement. IMP1734 readout later this year is the single event that determines...
209 Views
Primer: IMPACT Therapeutics (IMPACT HK) - Apr 2026
IMPACT Therapeutics is a clinical-stage biopharmaceutical company at the forefront of the targeted anti-cancer therapy space, with a strategic...
124 Views
APAC Healthcare Weekly (August 30)– CSPC Pharma, Akeso, Takeda, Astellas, Hanmi Pharm, SK Biopharma
CSPC and Akeso announced positive results from their respective Phase 3 trials for cancer drug candidates. Takeda got FDA approval for blood cancer...
103 Views
Pre-IPO IMPACT Therapeutics - Thoughts on the Pipeline, the Concerns and Valuation Outlook
​Senaparib shows promise in improving PFS but face commercialization challenge.Pipeline potential hinges on clinical success/approval...
357 Views